Back to search
FDAFDA · Food and drugs·Recall number D-0174-2020

Ranitidine Tablets, USP 75 mg 30 count bottles (NDC 30142-131-30) (Kroger)

Published November 13, 2019 · Recall initiated: October 1, 2019

Summary

FDA records drug Class II recall D-0174-2020, published November 13, 2019 and initiated October 1, 2019. Recalling firm: Dr. Reddy's Laboratories, Inc.; Status: Completed; Reported quantity: N/A; Lot: Batch Numbers: All lots within expiry. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Completed — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

CGMP Deviations: Presence of NDMA impurity detected in product.

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Dr. Reddy's Laboratories, Inc.
Distributor
Product was distributed to major distributors throughout the United States who may have further distributed the product.
Lot
Batch Numbers: All lots within expiry.
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Ranitidine Tablets, USP 75 mg 30 count bottles (NDC 30142-131-30) (Kroger) recalled?

Yes. FDA published recall D-0174-2020 on November 13, 2019. Reported hazard: CGMP Deviations: Presence of NDMA impurity detected in product.

What should I do if I have this product?

Voluntary: Firm initiated · Letter